291 related articles for article (PubMed ID: 27783533)
1. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
3. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden.
Heidelbaugh JJ; Stelwagon M; Miller SA; Shea EP; Chey WD
Am J Gastroenterol; 2015 Apr; 110(4):580-7. PubMed ID: 25781368
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).
Taylor DCA; Abel JL; Martin C; Doshi JA; Essoi B; Korrer S; Reasner DS; Carson RT; Hunter AG
J Med Econ; 2020 Oct; 23(10):1072-1083. PubMed ID: 32696684
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
7. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
11. Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
Lacy BE; Patel H; Guérin A; Dea K; Scopel JL; Alaghband R; Wu EQ; Mody R
PLoS One; 2016; 11(4):e0154258. PubMed ID: 27116612
[TBL] [Abstract][Full Text] [Related]
12. Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade.
Nellesen D; Chawla A; Oh DL; Weissman T; Lavins BJ; Murray CW
Postgrad Med; 2013 Mar; 125(2):40-50. PubMed ID: 23816770
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
[TBL] [Abstract][Full Text] [Related]
14. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.
Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT; Doshi JA
J Med Econ; 2014 Feb; 17(2):148-58. PubMed ID: 24168640
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome.
DiBonaventura M; Sun SX; Bolge SC; Wagner JS; Mody R
Curr Med Res Opin; 2011 Nov; 27(11):2213-22. PubMed ID: 21951105
[TBL] [Abstract][Full Text] [Related]
16. All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome.
Mitra D; Davis KL; Baran RW
Postgrad Med; 2011 May; 123(3):122-32. PubMed ID: 21566422
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of irritable bowel syndrome in China.
Zhang F; Xiang W; Li CY; Li SC
World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
[TBL] [Abstract][Full Text] [Related]
18. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
19. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain.
Nyrop KA; Palsson OS; Levy RL; Von Korff M; Feld AD; Turner MJ; Whitehead WE
Aliment Pharmacol Ther; 2007 Jul; 26(2):237-48. PubMed ID: 17593069
[TBL] [Abstract][Full Text] [Related]
20. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation.
Cash BD; Sharma A; Walker A; Laitman AP; Chang L
Neurogastroenterol Motil; 2023 Sep; 35(9):e14632. PubMed ID: 37332239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
